tiprankstipranks
Hemostemix Partners with CytoImmune, Boosts ACP-01 Production
Company Announcements

Hemostemix Partners with CytoImmune, Boosts ACP-01 Production

Story Highlights

Hemostemix (TSE:HEM) has released an update.

Don't Miss Our Christmas Offers:

Hemostemix Inc. has entered into a definitive Manufacturing Services Agreement with CytoImmune Therapeutics, marking the restart of production for its cardiovascular stem cell therapy, ACP-01, with initial sales expected to make the company self-funding. The agreement, involving a share issuance to CytoImmune, will also cover the production costs for the first batch of commercial treatments, targeting sales of $1.1 million. This strategic partnership aims to deliver life-changing treatments for patients with severe cardiovascular diseases while ensuring significant cash flow for Hemostemix shareholders.

For further insights into TSE:HEM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskHemostemix Raises $2.67M to Boost Stem Cell Research
TipRanks Canadian Auto-Generated NewsdeskHemostemix Secures $1.8M in Private Placement
TipRanks Canadian Auto-Generated NewsdeskHemostemix Launches $4M Financing for Stem Cell Therapy Growth
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App